Background Systemic-onset juvenile idiopathic arthritis does not always respond to available
treatments, including antitumour necrosis factor agents. We investigated the efficacy and …

Objective. Rapidly progressive interstitial lung disease (RP-ILD) is a rare but potentially fatal
complication of JDM. The aim of this study was to establish markers for the prediction and …

Macrophage-activation syndrome (MAS) is a potentially life-threatening complication of
systemic juvenile idiopathic arthritis (s-JIA). Tocilizumab (TCZ), a humanized anti-IL-6 receptor …

We evaluated the safety and efficacy of tocilizumab in polyarticular-course juvenile
idiopathic arthritis (pJIA) with polyarticular or oligoarticular onset. Patients received 8 mg/kg …

Objective. To assess the longterm safety and effectiveness of tocilizumab (TCZ) in systemic-onset
juvenile idiopathic arthritis (sJIA). Methods. The longterm extension phase of 2 pivotal …

The objective of this study was to evaluate the efficacy, pharmacokinetics, and safety of
adalimumab in patients with polyarticular juvenile idiopathic arthritis (JIA) in Japan. Patients …

Background: Cannabis use has increased among older adults. Few epidemiological studies
have examined the medical diseases reported for cannabis use, routes of cannabis …

Results of a randomised, placebo-controlled, phase III trial of tocilizumab in sJIA patients at
eight Japanese hospitals, as well as the first 48 weeks of an open-label extension, have …

Objectives: Systemic juvenile idiopathic arthritis (sJIA) is a rheumatic disease in childhood
characterised by systemic symptoms and a relatively poor prognosis. Peripheral leukocytes …

Macrophage activation syndrome (MAS) is a severe and potential life-threatening complication
of childhood systemic inflammatory disorders. Corticosteroids are commonly used as the …